DOI: 10.1111/j.1541-0420.2005.00339.x

Biometrics 61, 816â€“823
September 2005

Stratified Analysis in Randomized Trials with Noncompliance
Shigeyuki Matsui
Department of Pharmacoepidemiology, School of Public Health, Kyoto University,
Kyoto 606-8501, Japan
email: matsui@pbh.med.kyoto-u.ac.jp
Summary. This article develops methods for stratiï¬ed analyses of additive or multiplicative causal eï¬€ect on
binary outcomes in randomized trials with noncompliance. The methods are based on a weighted estimating
function for an unbiased estimating function under randomization in each stratum. When known weights
are used, the derived estimator is a natural extension of the instrumental variable estimator for stratiï¬ed
analyses, and test-based conï¬dence limits are solutions of a quadratic equation in the causal parameter.
Optimal weights that maximize asymptotic eï¬ƒciency incorporate variability in compliance aspects across
strata. An assessment based on asymptotic relative eï¬ƒciency shows that a substantial enhancement in
eï¬ƒciency can be gained by using optimal weights instead of conventional ones, which do not incorporate
the variability in compliance aspects across strata. Application to a ï¬eld trial for coronary heart disease is
provided.
Key words: Causal eï¬€ect; Eï¬ƒciency; Noncompliance; Randomization; Stratiï¬ed analysis.

1. Introduction
In clinical trials involving human beings, ethical considerations for study participants override scientiï¬c requirements.
Noncompliance with the intervention and study procedures
due to ethical reasons is thus inevitable in practice. In randomized trials with stratiï¬cation, the aspects of noncompliance are likely to vary from stratum to stratum, since stratiï¬ed factors may aï¬€ect noncompliance directly or through the
outcome of the trial. A current convention to cope with noncompliance is the intention-to-treat (ITT) analysis in which
participants are analyzed according to the treatment they
were assigned rather than the treatment actually received
(Fisher et al., 1990; Lee et al., 1991). However, an ITT estimate may represent the eï¬€ectiveness of treatment policy, and
it generally underestimates the treatment eï¬€ect (Schwartz
and Lellouch, 1967; Sheiner and Rubin, 1995; Piantadosi,
1997). An ITT null test, however, would be a valid Î± level
test of the sharp causal null hypothesis of treatment eï¬€ect
of Fisher (1935), although a loss of power can occur due to
noncompliance.
Recently, randomization-based estimation methods that
are essentially to apply a test of a sharp causal nonnull hypothesis of treatment eï¬€ect have been developed for
nonstratiï¬ed cases (Robins and Tsiatis, 1991; Mark and
Robins, 1993; Robins and Greenland, 1994; Sato, 1994, 2000).
For binary outcomes, Sato (1994) derived estimation formulae based on Fisherâ€™s exact test or its approximation for
counterfactual data had all participants been subjected to
the control treatment under a sharp nonnull hypothesis, and
pointed out connections to the instrumental variable method
(Angrist, Imbens, and Rubin, 1996). Satoâ€™s formulae are also
useful for sample size and power calculations that incorporate

compliance information (Sato, 2000). For stratiï¬ed cases, Sato
(1994) has also provided a stratiï¬ed-adjusted estimator for
risk diï¬€erence and risk ratio. However, this estimator does not
incorporate the variability in noncompliance aspects across
strata, which may incur a loss of eï¬ƒciency. In addition, ITTstratiï¬ed null tests, which are commonly used for testing the
sharp null hypothesis of treatment eï¬€ect, ignore this variability. In this article, we extend Satoâ€™s instrumental variable method to stratum-adjusted analyses by incorporating
this variability in noncompliance aspects across strata. An
assessment based on asymptotic relative eï¬ƒciency shows that
substantial eï¬ƒciency loss can occur when this variability is
ignored.

2. Randomization-Based Stratiï¬ed Analysis
Consider a randomized trial with K strata. In stratum k (k =
1, . . . , K), nk participants are randomly assigned to the test
treatment and mk participants to the control treatment. From
among the nk test-assigned participants, only nk ,1 participants
compliantly receive the test treatment and, of nk ,1 , xk ,1 develop an event, while the remaining nk ,0 participants receive
the control treatment and, of nk ,0 , xk ,0 develop an event. Similarly, from among the mk control-assigned participants, mk ,1
participants receive the test treatment and, of mk ,1 , yk ,1 develop an event, while the remaining mk ,0 receive the control
treatment and, of mk ,0 , yk ,0 develop an event. Let Nk = nk +
mk be the total number of participants and tk = xk + yk be
the total number of events in stratum k, where xk = xk,1 +
xk,0 and yk = y k,1 + y k,0 . The notations are summarized in
K
Table 1. Let N = k=1 Nk be the total number of participants across strata.

816

Stratiï¬ed Analysis in Randomized Trials with Noncompliance

817

Table 1
Notation for stratum k (k = 1, . . . , K )
Stratum
of events

Group

No. of
participants

No. of
events

k

Test

nk

xk

Control

mk

yk

Total

Nk

tk

Our randomization-based analysis needs three assumptions: the stable unit treatment value assumption (SUTVA),
the exclusion restriction assumption (Angrist et al., 1996),
and a causal eï¬€ect model. Let Z be the N-dimensional vector
of treatment assignment for all N participants with ith element Zi , and let Di be an indicator for whether participant
i receives the test treatment, i.e., it takes 1 if the test treatment is received and 0 otherwise. We deï¬ne Yi (Z, D) to be
a random binary outcome of whether participant i develops
an event, given the treatment assignment Z and the vector
of treatment received D. The SUTVA is to assume that the
binary outcome for each participant is unrelated to the treatment status of other participants, i.e., Yi (Z, D) = Yi (Z , D )
if Zi = Z i and Di = Di , which allows us to write Yi (Z, D) as
Yi (Zi , Di ). The exclusion restriction is the assumption that
the binary outcome is not directly aï¬€ected by the treatment
assignment, but only by the treatment actually received, i.e.,
Yi (Z, D) = Yi (Z , D) for every Z, Z and for every D. Alternatively, for participant i in stratum k, let Yki (dki ) be the
random binary outcome and let P ki,dki = E{Y ki (dki )} be the
potential risk for the treatment actually received Dki . Note
that the potential risk, Pki ,0 , can be regarded as a baseline
risk for participant i in stratum k. For the two potential risks,
Pki ,1 and Pki ,0 , we assume an additive causal eï¬€ect, P ki,1 âˆ’
P ki,0 = Î´ 0 , or a multiplicative causal eï¬€ect, P ki,1 /P ki,0 = Ï0 ,
where Î´ 0 and Ï0 are unknown constants for all participants
(k = 1, . . . , K; i = 1, . . . , Nk ). Subsequently, we provide estimation procedures for both the additive causal eï¬€ect and the
multiplicative causal eï¬€ect. We assume a large-stratum limiting model (Hauck, 1979) in which the number of strata K
remains ï¬xed but the individual cell sizes become large.
2.1 Additive Causal Eï¬€ect
Provided that Î´ 0 is known, we could estimate the number of
events under a counterfactual situation in which all participants received the control as xâˆ—k (Î´ 0 ) = xk âˆ’ Î´ 0 nk,1 for the
test group and y âˆ—k (Î´ 0 ) = yk âˆ’ Î´ 0 mk,1 for the control group
in stratum k. Randomization guarantees that treatment assignment is independent of baseline covariates including Pki ,0 ,
and hence, E{xâˆ—k (Î´ 0 )/nk } = E{y âˆ—k (Î´ 0 )/mk } (k = 1, . . . , K).
We can then have an unbiased estimating function under
randomization,
S(Î´) =

K

k=1


wk (Î´)

xâˆ—k (Î´) ykâˆ— (Î´)
âˆ’
nk
mk


,

where wk (Î´) is a weight function, possibly a function of Î´, for
stratum k. We assume that wk (Î´ 0 ) converges in probability

Treatment
actually received

No. of
participants

No. of
events

Test
Control
Test
Control

nk ,1
nk ,0
mk ,1
mk ,0

xk ,1
xk ,0
yk ,1
yk ,0

to a constant under the large-stratum limiting model (k =
1, . . . , K). A point estimate of Î´ 0 is the solution of the equation
S(Î´) = 0. An estimator of the variance of S(Î´ 0 ) may be given
by
V (Î´0 ) =

K



wk2 (Î´0 )



xâˆ—k (Î´0 ) + ykâˆ— (Î´0 )

nk mk Nk

k=1



Nk âˆ’ xâˆ—k (Î´0 ) âˆ’ ykâˆ— (Î´0 )

.

The hypothesis Î´ = Î´  can be tested using the test statistic
Z(Î´  ) = S(Î´  )/[V (Î´  )]1/2 , which follows the standard normal
distribution approximately under Î´  = Î´ 0 . Note that, for the
sharp null hypothesis of treatment eï¬€ect, Î´ = 0, this test
reduces to an ITT-stratiï¬ed test.
Several speciï¬cations can be considered for the weights,
wk (Î´). When comparing speciï¬cations in terms of eï¬ƒciency,
we use an optimal criterion for unbiased estimating functions proposed by Godambe (1960). Under certain general
regularity conditions, this implies maximizing the asymptotic eï¬ƒciency, AE = N âˆ’1 E2 [dS (Î´)/dÎ´|Î´=Î´0 ]/E[S 2 (Î´ 0 )]. The
Appendix shows that the optimal weight for stratum k may be
given by
wkA (Î´0 ) = 

rk nk mk Nk

,
xâˆ—k (Î´0 ) + ykâˆ— (Î´0 ) Nk âˆ’ xâˆ—k (Î´0 ) âˆ’ ykâˆ— (Î´0 )

(1)

where
rk =

nk,1
mk,1
âˆ’
nk
mk

reï¬‚ects the noncompliance aspects in stratum k (k =
1, . . . , K). When all participants in stratum k are compliant,
rk = 1. The weights w A
k (Î´ 0 ) are unknown, since they include
the unknown constant Î´ 0 . Under the assumption
Nk that the averaged baseline risk in stratum k, PÌ„k,0 = i=1
Pki,0 /Nk , is
constant for all k, we have
wkB =

rk nk mk
Nk

for stratum k. This weight does not include the unknown constant Î´ 0 , hence, w Bk is known (k = 1, . . . , K). Because weights
B
wA
k (Î´ 0 ) and w k include rk , analyses using these weights incorporate the variability in noncompliance aspects across strata.
On the other hand, conventional weights that ignore this
variability or assume that all participants are compliant include those in the null weighted least square (WLS) estimator given by Rothman and Boice (1979) (also see Greenland
and Robins, 1985) and those in the Mantelâ€“Haenszel (MH)

Biometrics, September 2005

818

estimator given by Greenland and Robins (1985). The weight
for stratum k in the null-WLS estimator may be given by
wkC (Î´0 ) = 

nk mk Nk

,
xâˆ—k (Î´0 ) + ykâˆ— (Î´0 ) Nk âˆ’ xâˆ—k (Î´0 ) âˆ’ ykâˆ— (Î´0 )

while the weight for stratum k in the MH estimator is given
by
nk m k
.
wkD =
Nk
Note that the weight w Ck (Î´ 0 ) is unknown, while w D
k is known.
Under the assumption that rk is constant for all k, w A
k (Î´ 0 ) and
w Bk reduce to w Ck (Î´ 0 ) and w D
k , respectively (see Appendix). Regarding the test of the sharp null hypothesis of Î´ = 0, we have
an asymptotically eï¬ƒcient test derived from the additive risk
model given by Radhakrishna (1965) when weights wCk (Î´ 0 ) are
used, while we have the Cochran and Mantelâ€“Haenszel tests
(Cochran, 1954; Mantel and Haenszel, 1959) when weights w D
k
are used.
For known weights, wk (k = 1, . . . , k), the point estimator
is explicitly given by



Î´Ì‚ = 

wk dk

k

,

(2)

wk rk

k

where dk = xk /nk âˆ’ yk /mk is the ITT risk diï¬€erence between
treatment groups (k = 1, . . . , K). If there is no stratiï¬cation
(K = 1), Î´Ì‚ reduces to the instrumental variable estimator
(Sato, 1994; Angrist et al., 1996; Greenland, 2000). Approximate 1 âˆ’ Î± test-based conï¬dence limits are obtained by solving Z(Î´) = Â±z Î±/2 , which yields a quadratic equation in Î´ with
explicit solutions,
[lower limit, upper limit]



=
where
A=



B+
2C
âˆš
,
2
B + B âˆ’ 4AC

2
2
+ zÎ±/2

wk rk

k

B=2


k

2
âˆ’ zÎ±/2

C =


k

wk rk


k

 


k

âˆš



B 2 âˆ’ 4AC
,
2A

(3)

wk2
(nk,1 + mk,1 )2 ,
nk mk Nk



wk dk

k

wk2
(Nk âˆ’ 2tk )(nk,1 + mk,1 ),
nk mk Nk

wk dk

2
2
âˆ’ zÎ±/2


k

wk2
tk (Nk âˆ’ tk ).
nk mk Nk

Here, zq is the upper q point of the standard normal distribution. Sato (1994) obtained the same formula for point estimate and conï¬dence limits using the MH weights, w D
k . On the
C
other hand, when unknown weights such as w A
k (Î´ 0 ) or w k (Î´ 0 )
are used, explicit solutions may not be obtained; hence, a
numerical search procedure or the following simple iterative
procedure may be adopted. Step 1: set an initial value for Î´ 0 ,
for example, the solution when known weights such as w Bk or

wD
k are used; step 2: calculate the weights as if this value for
Î´ 0 is the true solution; and step 3: obtain a new solution for
Î´ 0 , assuming that the calculated weights are known, in order to update the weights. Subsequently, iterate step 2 and
step 3 until the solution converges.
The rk can take a value within [âˆ’1, 1] in principle, but
it generally takes only a positive value in most trials. As
Greenland (2000) pointed out, the participants can be classiï¬ed into two types: cooperators and noncooperators. Cooperators would always comply with the assigned treatment, while
noncooperators would not. Noncooperators may be composed of
always-takers, never-takers, and deï¬ers (Angrist et al., 1996).
Always-takers always take the test treatment, while nevertakers never take the test treatment and always take the control treatment. Deï¬ers would always take the opposite of the
assigned treatment. In most trials, there are a few deï¬ers because they may dissent from participating in the trial during
the process of the informed consent and actually may not participate in the trial; hence, we exclude deï¬ers in the sequel.
This corresponds to the monotonicity assumption in Angrist
et al. (1996). Let q CO
and q AT
be the proportion of cooperak
k
tors and always-takers, respectively, in stratum k in the trial.
AT
Because randomization assures E(nk,1 /nk ) = q CO
k + q k and
AT
CO
E(mk,1 /mk ) = q k , E(rk ) = q k , where the expectation refers
to the average overall possible patterns of random assignment.
Hence, rk would take a positive value.
2.2 Multiplicative Causal Eï¬€ect
Results paralleling those for the additive causal eï¬€ect can be
obtained for the multiplicative causal eï¬€ect. We replace xâˆ—k (Î´),
yâˆ—k (Î´), and wk (Î´) with xâˆ—k (Ï) = xk,1 /Ï + xk,0 , y âˆ—k (Ï) = y k,1 /Ï +
y k,0 , and wk (Ï), respectively. The Appendix shows that the
optimal weight for stratum k, w A
k (Ï0 ), is given by (1) with
replacement of rk with sk , where sk = xk,1 /nk âˆ’ y k,1 /mk . Because sk can be expressed as (nk,1 /nk )(xk,1 /nk,1 ) âˆ’ (mk,1 /
mk )(y k,1 /mk,1 ), sk reï¬‚ects the risk of the event for those who
receive the test treatment as well as the noncompliance aspects in stratum k, unlike rk for the additive causal eï¬€ect.
Under the assumption that the averaged baseline risk in stratum k, PÌ„k,0 , is constant for all k, we have w Bk = sk nk mk /Nk
for stratum k. As conventional weights, one may use a nullWLS weight, w Ck (Ï0 ) = nk mk /{Nk âˆ’ xâˆ—k (Ï0 ) âˆ’ y âˆ—k (Ï0 )}, under
the assumption that all participants are compliant or the MH
estimator for risk ratio (Greenland and Robins, 1985), which
is given by w D
k in Section 2.1 for the additive causal eï¬€ect.
B
C
D
The w A
k (Ï0 ) and w k reduce to w k (Ï0 ) and w k , respectively,
under the assumption that all participants are compliant (see
Appendix). Regarding the test of the sharp null hypothesis
of Ï = 1, we have an asymptotically eï¬ƒcient test derived
from a risk-ratio model proposed by Radhakrishna (1965)
when weights w Ck (Ï0 ) are used, while we have the Cochran and
Mantelâ€“Haenszel tests (Cochran, 1954; Mantel and Haenszel,
1959) when weights w D
k are used.
For known weights, wk (k = 1, . . . , K), the estimator is explicitly given by



ÏÌ‚ = 

wk sk

k

k

,
wk uk

(4)

Stratiï¬ed Analysis in Randomized Trials with Noncompliance
where uk = y k,0 /mk âˆ’ xk,0 /nk (k = 1, . . . , K). If there is no
stratiï¬cation (K = 1), ÏÌ‚ reduces to the instrumental variable
estimator for relative risk (Sato, 1994; Cuzick, Edward, and
Segnan, 1997; Greenland, 2000). Approximate 1 âˆ’ Î± testbased conï¬dence limits are given by (3), where
A=



2



B
C

k



wk2
(xk,0 + yk,0 )(Nk âˆ’ xk,0 âˆ’ yk,0 ),
nk mk Nk



wk sk

k
2
+ zÎ±/2

C =

wk2
nk mk Nk

2
+ zÎ±/2

k


k

wk2
(xk,1 + yk,1 )2 .
nk mk Nk

CO
and
Arguments that apply to rk apply to sk as well. Let PÌ„k,0
be the averaged baseline risk for cooperators and alwaystakers, respectively, in stratum k. Because randomization asCO
AT
sures E(xk,1 /nk ) = Ï0 (qkCO PÌ„0,k
+ qkAT PÌ„0,k
) and E(y k,1 /mk ) =
AT AT
CO CO
Ï0 qk PÌ„0,k , E(sk ) = Ï0 qk PÌ„0,k . Hence, sk would take a positive
value in most trials. Furthermore, we can have a range for
NC
E(sk ). Let PÌ„k,0
be the averaged baseline risk for noncooperCO
+ (1 âˆ’
ators in stratum k. From the equation PÌ„k,0 = qkCO PÌ„k,0
CO
NC
CO
qk )PÌ„k,0 , we have a range for PÌ„k,0 ,
AT
PÌ„k,0

max

0,

PÌ„k,0 âˆ’ 1 âˆ’ qkCO
qkCO

Additive
causal eï¬€ect

Multiplicative
causal eï¬€ect

Î¸k Î·k
4Ï€k (1 âˆ’ Ï€k )
Î¸k Î·k
4
Î·k
4Ï€k (1 âˆ’ Ï€k )
Î·k
4

Ïˆk Î·k
4Ï€k (1 âˆ’ Ï€k )
Ïˆk Î·k
4
Î·k
4(1 âˆ’ Ï€k )
Î·k
4

wk uk

(xk,1 + yk,1 ){Nk âˆ’ 2(xk,0 + yk,0 )},

2

wk sk

D

k


k



Weight
A

2
âˆ’zÎ±/2

B = âˆ’2

Table 2
The form of wÌƒk for each of the four weights for the additive
or multiplicative causal eï¬€ect

wk uk

k

819


, min

PÌ„k,0
1, CO
qk

.

(5)

We then have a range for E(sk ). Note that q CO
can be estik
mated by rk (see Section 2.1).
3. Eï¬ƒciency Comparison
We assess how eï¬ƒciency is enhanced by using the optimal
weights that incorporate variability in noncompliance aspects across strata instead of using the conventional weights.
We supposed randomized trials with three strata (K = 3).
The participants were assigned to the test treatment or its
control with equal probability. We assumed a large-stratum
p
p
limiting model in which N âˆ’1 Nk â†’ Î·k (>0), PÌ„k,0 â†’ Ï€k (>0),
p
p
rk â†’ Î¸k (>0), and sk â†’ Ïˆk (>0) (k = 1, . . . , K). Under random assignment of two treatments with equal probability, g, Nâˆ’1 w, and N Î£ in the Appendix would converge in
probability to gÌƒ = (gÌƒ1 , . . . , gÌƒK ) , wÌƒ = (wÌƒ1 , . . . , wÌƒK ) , and Î£Ìƒ =
âˆ’ Ï€K )
diag( 4Ï€1 (1Î·1âˆ’ Ï€1 ) , . . . , 4Ï€K (1
), respectively. Here, gÌƒk is Î¸k for
Î·K
the additive causal eï¬€ect and gÌƒk is Ïˆ k for the multiplicative
causal eï¬€ect. Table 2 summarizes the form of wÌƒk for each
of the four types of weights for the additive or multiplicative causal eï¬€ects. Then, AE would converge in probabil = (wÌƒ gÌƒ)2 /wÌƒ Î£ÌƒwÌƒ. The asymptotic relative eï¬ƒciency
ity to AE
(ARE) of weight A with respect to weight B is deï¬ned as
 wÌƒ=wÌƒA /AE
 wÌƒ=wÌƒB , and the ARE of weight A with respect to
AE
the other weights can be similarly deï¬ned.

With respect to Î¸k , we set 1.0, 0.7, 0.4, or 0.1; hence, we
had 64 (=43 ) patterns for Î˜ = (Î¸1 , Î¸2 , Î¸3 ), where the value
1.0 for Î¸k indicates that all participants in stratum k are compliant. We set Ï€ k to be 0.1 or 0.3; hence, we had 8 (=23 )
patterns for Î  = (Ï€ 1 , Ï€ 2 , Ï€ 3 ) for each Î˜. We set Î· 1 = Î· 2 =
Î· 3 (=1/3), for which the estimator using the MH weights, w D
k,
coincides with an unweighted estimator. For each conï¬guration, we calculated the ARE of weight A with respect to the
other weights and performed 1000 simulations to obtain the
empirical variance of the estimate. In the simulations, we assumed 200 participants in each stratum with noncompliance
occurring only in the test group and noncompliers receiving
the control treatment.
3.1 Additive Causal Eï¬€ect
Table 3 summarizes the ARE of weights, w A
k (Î´), with respect
to the other weights, w Bk , w Ck (Î´), and w D
k and the ratio of the
variance of the simulated estimate using weights, w Bk , w Ck (Î´),
A
and w D
k divided by that using weights, w k (Î´), for 10 selected
conï¬gurations. The results of the variance of simulated estimate paralleled those of the ARE. For fully compliant scenarios (conf. 1, 2), as one would expect, the eï¬ƒciency for all
weights under constant Ï€ k across strata was the same (conf.
1), but there is some eï¬ƒciency loss for the ï¬xed weights, i.e.,
weights B and D, under nonconstant Ï€ k (conf. 2). The same
results were obtained for noncompliant scenarios (Î¸k < 1.0
for some k) with constant Î¸k across strata (conf. 3, 4). The
greater the variability in Î¸k across strata, the greater the enhancement in eï¬ƒciency by using optimal weight A, instead of
conventional weights C or D (compare conf. 5, 6 and conf. 7,
8). For a given variability in Î¸k , there is greater enhancement
for smaller Î¸k (compare conf. 5, 6 and conf. 9, 10). The ARE
with respect to weights C and D can reach 2.76 and 3.97, respectively. For conï¬gurations with low noncompliance rates,
such as Î¸k â‰¥ 0.7 for all k, as seen in many trials including
those for new drug applications, the eï¬ƒciency when weight A
was used was comparable with those when weight C was used
(the maximum being 1.03 in the ARE). Meanwhile, the eï¬ƒciency could be substantially greater than that when weight
D was used (the maximum being 1.40 in the ARE).
3.2 Multiplicative Causal Eï¬€ect
As a reminder, the optimal weight w A
k (Ï0 ) includes sk that
reï¬‚ects the baseline risk of the event as well as the noncompliance aspects in stratum k, unlike rk for the additive
causal eï¬€ect. We ï¬rst suppose a random noncompliance scenario in which the noncompliance behavior of a participant

Biometrics, September 2005

820

Table 3
The ARE of weight A with respect to the other weights (left) and the ratio of the variance of the simulated estimate using weight
B, C, or D divided by that using weight A (right) for each conï¬guration of Î˜ and Î  for the additive causal eï¬€ect model. The
empirical variance was obtained from 1000 simulations under Î´ = 0.1.
Conf.
1
2
3
4
5
6
7
8
9
10
a FS:

(Î¸1 , Î¸2 , Î¸3 )
(1.0,
(1.0,
(0.7,
(0.7,
(1.0,
(1.0,
(1.0,
(1.0,
(0.4,
(0.4,

1.0,
1.0,
0.7,
0.7,
0.7,
0.7,
0.1,
0.1,
0.1,
0.1,

1.0)
1.0)
0.7)
0.7)
0.7)
0.7)
0.1)
0.1)
0.1)
0.1)

(Ï€ 1 , Ï€ 2 , Ï€ 3 )
(0.1,
(0.1,
(0.1,
(0.1,
(0.1,
(0.3,
(0.1,
(0.3,
(0.1,
(0.3,

0.1,
0.1,
0.1,
0.1,
0.3,
0.1,
0.3,
0.1,
0.3,
0.1,

0.1)
0.3)
0.1)
0.3)
0.3)
0.1)
0.3)
0.1)
0.3)
0.1)

Weight B ARE FSa
1.00,
1.16,
1.00,
1.16,
1.19,
1.19,
1.01,
1.01,
1.07,
1.07,

1.04
1.07
1.02
1.13
1.10
1.13
1.01
1.01
1.06
1.07

Weight C ARE FS
1.00,
1.00,
1.00,
1.00,
1.03,
1.02,
1.59,
2.76,
1.33,
1.56,

1.00
1.00
1.00
1.00
0.99
1.05
1.50
2.83
1.30
1.50

Weight D ARE FS
1.00,
1.16,
1.00,
1.16,
1.40,
1.06,
3.97,
1.35,
2.65,
1.07,

1.04
1.07
1.01
1.13
1.25
1.05
3.33
1.41
2.33
1.06

ï¬nite sample, 200 participants in each stratum. Standard errors of entries are approximately 6% of entries.

is not aï¬€ected by the baseline risk of that participant, but
is directly aï¬€ected by stratiï¬ed factors. Under this scenario,
E(sk ) may reduce to Ï0 qkCO PÌ„k,0 , which converges in probability to Ï0 Î¸k Ï€ k . For the same selected conï¬gurations as those
in Table 3 for the additive causal eï¬€ect, Table 4 summarizes
the ARE of weights, w A
k (Ï), with respect to the other weights,
w Bk , w Ck (Ï), and w D
k and the ratio of the variance of the logtransformed simulated estimate using weights, w Bk , w Ck (Ï), and
A
wD
k divided by that using w k (Ï), which approximates to the
variance ratio under a large sample size. For conï¬gurations
with small Î¸k (conf. 7, 9, 10), some simulated estimates were
negative due to a negative value of uk or were not obtained
due to division by zero in (4), for which the estimate was set
to be a missing value. The number of missing cases decreased
as the sample size increased, e.g., missing cases did not appear when the number of participants in each stratum was
2000, but the results were similar. Overall, under the random
noncompliance scenario, we had similar results as those for
the additive causal eï¬€ect model.
A substantial enhancement in eï¬ƒciency by using optimal
weight A instead of conventional weights C or D may, however,

be obtained under nonrandom noncompliance scenarios even
when the noncompliance rates are low such as Î¸k â‰¥ 0.7 for all
k. From range (5) for the averaged baseline risk for cooperators,
CO
, we have a possible conï¬guration Î˜ = (1.0, 0.7, 0.7), Î 
PÌ„k,0
CO
CO
= (0.5, 0.3, 0.3), and (Ï€ CO
1 , Ï€ 2 , Ï€ 3 ) = (0.50, 0.40, 0.05), for
which the ARE of weight A with respect to weights C and D
were 1.22 and 1.39, respectively.
4. Example
We illustrate the developed methods using the data from the
multiple risk factors intervention trial (MRFIT; MRFIT Research Group, 1982). The MRFIT was a large ï¬eld trial to
test the eï¬€ect of a multifactor intervention program on mortality from coronary heart disease (CHD) in middle-aged men.
The intervention consisted of dietary advice to reduce blood
cholesterol, smoking cessation counseling, and hypertension
medication. The participants were randomly assigned to the
intervention program or its control, where the members of the
control group were referred to their usual physicians for treatment. With respect to the intervention eï¬€ects on the reduction of the three risk factors, only the treatment for cigarette

Table 4
The ARE of weight A with respect to the other weights (left) and the ratio of the variance of the log-transformed simulated
estimate using weight B, C, or D divided by that using weight A (right) for each conï¬guration of Î˜ and Î  for the multiplicative
causal eï¬€ect model. The empirical variance was obtained from 1000 simulations under Ï = 1.5.
Conf.
1
2
3
4
5
6
7b
8
9b
10b
a FS:

(Î¸1 , Î¸2 , Î¸3 )
(1.0,
(1.0,
(0.7,
(0.7,
(1.0,
(1.0,
(1.0,
(1.0,
(0.4,
(0.4,

1.0,
1.0,
0.7,
0.7,
0.7,
0.7,
0.1,
0.1,
0.1,
0.1,

1.0)
1.0)
0.7)
0.7)
0.7)
0.7)
0.1)
0.1)
0.1)
0.1)

(Ï€ 1 , Ï€ 2 , Ï€ 3 )
(0.1,
(0.1,
(0.1,
(0.1,
(0.1,
(0.3,
(0.1,
(0.3,
(0.1,
(0.3,

0.1,
0.1,
0.1,
0.1,
0.3,
0.1,
0.3,
0.1,
0.3,
0.1,

0.1)
0.3)
0.1)
0.3)
0.3)
0.1)
0.3)
0.1)
0.3)
0.1)

Weight B ARE FSa
1.00,
1.11,
1.00,
1.11,
1.06,
1.07,
1.10,
1.00,
1.19,
1.01,

0.98
1.07
0.98
1.07
1.08
1.00
1.17
1.00
1.10
1.03

Weight C ARE FS
1.00,
1.00,
1.00,
1.00,
1.02,
1.03,
2.99,
1.38,
1.51,
1.23,

0.97
0.99
0.95
0.98
1.01
1.05
5.02
1.63
1.75
1.48

Weight D ARE FS
1.00,
1.01,
1.00,
1.01,
1.00,
1.08,
2.38,
1.64,
1.34,
1.41,

0.97
1.01
0.96
1.00
0.99
1.15
4.01
2.01
1.32
1.99

ï¬nite sample, 200 participants in each stratum. Standard errors of entries are approximately 6% of entries.
of 1000 simulations, 11 missing cases for weights A, B, and D, and 19 missing cases were missing for weight C for conf. 7. For weights A,
B, C, and D, 94, 89, 87, and 84 missing cases, respectively, for conf. 9. Eight missing cases for all weights for conf. 10.
b Out

Stratiï¬ed Analysis in Randomized Trials with Noncompliance

821

Table 5
The status of cigarette smoking and the incidence of CHD deaths during period of follow-up of 7 years in MRFIT
Stratum
no. of cigarettes
at baseline
<30

â‰¥30

a Proportion

No. of
participants

CHD
death

Test

1260

25

Control

1180

26

Total

2440

51

Test

2573

44

Control

2650

48

Total

5223

92

Group

Smoking status
at 1 year

No. of
participants

CHD
death

Quit
Not quit
Quit
Not quit

454 (36%)a
806
159 (13%)
1021

6
19
3
23

Quit
Not quit
Quit
Not quit

537 (21%)
2036
215 (8%)
2435

5
39
1
47

that quit smoking 1 year after entry in each group.

smoking was eï¬€ective, compared with those for modifying
blood cholesterol and hypertension; the group diï¬€erence in
number of smokers at 12 months was 15.4%, and the diï¬€erence in terms of a mean change in the number of cigarettes
smoked per day exceeded the design goal by 45%. In contrast,
the group diï¬€erence in diastolic blood pressure averaged over
annual visits was only 4% (75% of the design goal), and the
average diï¬€erence in serum cholesterol was only 2% (50% of
the design goal) (MRFIT Research Group, 1982). Here we restrict our attention to the eï¬€ects of quitting cigarette smoking as in Mark and Robins (1993) and Sato (2000) because
of the paucity of achieved diï¬€erences on the other risk factors, although the trial actually investigated the eï¬€ects of a
mixture of medication and education for heart disease, and
hence, the states of classroom attendance should also be incorporated when deï¬ning treatment compliance. We regard
the number of cigarettes per day at baseline (<30 or â‰¥30 per
day) as a stratiï¬ed factor. Table 5 summarizes the incidence
of CHD deaths during the follow-up period of 7 years based
on the treatment assigned and the actual smoking status 1
year after entry for each stratum. The proportions of participants who did not quit smoking in the test group were
extraordinarily high, despite exceeding design expectations.
As expected, the proportions of participants quitting smoking varied over two strata; the proportions in the stratum of
the number of cigarettes â‰¥30 per day were less than those in
the stratum of the number of cigarettes <30 per day for each
group.
Tables 6 and 7 show a full result of the analysis of MRFIT
for the additive and multiplicative causal eï¬€ect, respectively,
where the instrumental variable (IV) estimator for stratum k
is given by dk /rk for the additive causal eï¬€ect and sk /uk for the
multiplicative causal eï¬€ect (k = 1, . . . , K). The upper limit
was not obtained for the multiplicative causal eï¬€ect. It was
indicated that quitting smoking had eï¬€ects that reduced the
risk of CHD death for all strata. Due to high noncompliance
rates across strata, the IV estimates indicated a much greater
eï¬€ect of quitting smoking than the ITT estimates. The results
of stratiï¬ed analysis using four weights, weights A, B, C, and
D, were comparable.

We also calculated the approximate ARE of weight A with
respect to the other weights under the additive causal eï¬€ect
model. From Table 5, we set (Î· 1 , Î· 2 ) = (0.32, 0.68), (Î¸1 , Î¸2 ) =
(0.23, 0.13). Based on the stratiï¬ed adjusted estimates for
causal parameters when weight A is used in Table 6, we could
estimate (Ï€ 1 , Ï€ 2 ) as (0.023, 0.019). For this conï¬guration, the
ARE of weight A with respect to weights B, C, and D were
1.01, 1.08, and 1.04, respectively, which indicated a small enhancement in eï¬ƒciency by using weight A instead of the other
weights. However, there would be a possibility of substantial
enhancement in eï¬ƒciency when the stratum with the number
of cigarettes per day at baseline <30 is divided into two strata
as is seen in medical or epidemiological literature. Stratum 1
with the number of cigarettes per day <10 was designated as
light smokers, and stratum 2 with the number of cigarettes
per day â‰¥10, but <30 was designated as moderate smokers.
Stratum 3 was the stratum with the number of cigarettes
per day at baseline â‰¥30 and was designated as heavy smokers. The r1 for light smokers is expected to be higher than the
others. Regarding the averaged baseline risk, we assumed that
(Ï€ 1 , Ï€ 2 , Ï€ 3 ) = (0.023, 0.023, 0.019). Conï¬gurations satisfying
Î· 1 + Î· 2 = 0.32, Î· 3 = 0.68, (Î· 1 Î¸1 + Î· 2 Î¸2 )/(Î· 1 + Î· 2 ) = 0.23, and
Table 6
Estimation results for the additive causal eï¬€ect in MRFIT
Analysis by stratum
No. of cigarettes
per day at baseline

ITT risk
diï¬€erence
dk (%)

IV estimate
dk /rk (%)

<30
â‰¥30

âˆ’0.22
âˆ’0.10

âˆ’0.97
âˆ’0.79

Stratum-adjusted analysis
Weight
A
B
C
D

Point estimate (%)
âˆ’0.89
âˆ’0.90
âˆ’0.87
âˆ’0.87

95% CI (%)
[âˆ’5.54,
[âˆ’5.61,
[âˆ’5.72,
[âˆ’5.57,

2.36]
2.36]
2.49]
2.47]

P-value
0.640
0.640
0.662
0.654

Biometrics, September 2005

822

Table 7
Estimation results for the multiplicative causal eï¬€ect
in MRFIT
Analysis by stratum
No. of cigarettes
per day at baseline

ITT risk ratio
(xk /nk )/(yk /mk )

IV estimate
sk /uk

0.90
0.94

0.50
0.61

<30
â‰¥30
Stratum-adjusted analysis
Weight
A
B
C
D
a The

Point estimate
0.55
0.55
0.54
0.56

95% CI
[0.16,
[0.16,
[0.16,
[0.17,

â€“a ]
â€“]
â€“]
â€“]

P-value
0.646
0.641
0.639
0.654

upper limit was not obtained.

Î¸3 = 0.13 may include (i) (Î· 1 , Î· 2 , Î· 3 ) = (0.10, 0.22, 0.68) and
(Î¸1 , Î¸2 , Î¸3 ) = (0.40, 0.15, 0.13) and (ii) (Î· 1 , Î· 2 , Î· 3 ) = (0.05,
0.27, 0.68) and (Î¸1 , Î¸2 , Î¸3 ) = (0.66, 0.15, 0.13). The ARE of
weight A with respect to weights B, C, and D were 1.01, 1.23,
and 1.18, respectively, for the ï¬rst conï¬guration, while 1.01,
1.47, and 1.41, respectively, for the second conï¬guration.

5. Discussion
In this article, we have developed methods of stratiï¬ed analyses for the additive or multiplicative causal eï¬€ect on binary outcomes in randomized trials with noncompliance. The
methods are an extension of the instrumental variable method
proposed by Sato (1994) developed by incorporating optimal weights that reï¬‚ect the variability in noncompliance
aspects across strata. An assessment based on asymptotic relative eï¬ƒciency shows that a substantial enhancement in eï¬ƒciency can be gained by using the optimal weights instead of
the conventional weights, such as those in the weighted least
square or Mantelâ€“Haenszel methods. The results suggest that
the optimal weights rather than the conventional weights be
used, both in estimating the causal eï¬€ect and in testing the
sharp causal null hypothesis of treatment eï¬€ect. Particularly,
a stratiï¬ed null test with the optimal weights should be distinguished from conventional ITT-stratiï¬ed null tests, which
are commonly used for testing the sharp causal null hypothesis of treatment eï¬€ect. The optimal weights can also improve
sample size and power calculations proposed by Sato (2000).
In our randomization-based methods, rk and sk reï¬‚ect the
noncompliance aspects in stratum k for the additive and multiplicative causal eï¬€ect model, respectively. As noted previously, they represent quantities concerning cooperators in
stratum k. In the extreme situation where rk = 0, there are
no cooperators in stratum k, and the random assignment no
longer aï¬€ects intervention for all participants in this stratum.
Therefore, we could not obtain any information regarding the
causal eï¬€ect from this stratum. In this situation, the optimal weight for this stratum is zero, discarding any information from this stratum, while the conventional weights for this
stratum may not be zero as it collects noise in outcomes from
this stratum. Thus, rk relates to the amount of information
regarding the causal eï¬€ect gained from stratum k, and it is

rational to take into account the magnitude of rk in stratiï¬ed
analyses, which is carried out using the optimal weight.
Although a constant treatment eï¬€ect over all participants
is assumed in the causal model, the point estimator in (2) or
(4) can be interpreted as the treatment eï¬€ect on the averaged
risk for cooperators (also see Angrist et al., 1996 for the addiCO
AT
tive causal eï¬€ect under no stratiï¬cation). Let PÌ„k,1
, PÌ„k,1
, and
NT
be the averaged risk for cooperators, always-takers, and
PÌ„k,1
never-takers, respectively, had all participants in stratum k received the test treatment. For the additive causal eï¬€ect, since
CO
AT
NT
E(xk /nk ) = qkCO PÌ„k,1
+ qkAT PÌ„k,1
+ qkNT PÌ„k,0
and E(yk /mk ) =
CO CO
AT AT
NT NT
qk PÌ„k,0 + qk PÌ„k,1 + qk PÌ„k,0 , we have the expected value of
CO
CO
âˆ’ PÌ„k,0
). Meanthe ITT risk diï¬€erence, E(dk ) = qkCO (PÌ„k,1
CO
while, as indicated in Section 2.1, E(rk ) = q k . Hence, the
point estimator (2) for the constant causal eï¬€ect Î´ 0 represents a stratum-adjusted diï¬€erence of the averaged risk for
cooperators. With respect to the multiplicative causal eï¬€ect,
CO
AT
AT
CO
E(sk ) = qkCO PÌ„k,1
+ qkAT PÌ„k,1
âˆ’ qkAT PÌ„k,1
= qkCO PÌ„k,1
and E(uk ) =
CO CO
NT NT
NT NT
CO CO
qk PÌ„k,0 + qk PÌ„k,0 âˆ’ qk PÌ„k,0 = qk PÌ„k,0 . Hence, the point estimator (4) for the constant causal eï¬€ect Ï0 represents a
stratum-adjusted ratio of the averaged risk for cooperators.

References
Angrist, J. D., Imbens, G. W., and Rubin, D. B. (1996). Identiï¬cation of causal eï¬€ects using instrumental variables.
Journal of the American Statistical Association 91, 444â€“
455.
Cochran, W. G. (1954). Some methods for strengthening the
Ï‡2 test. Biometrics 10, 417â€“451.
Cuzick, J., Edward, R., and Segnan, N. (1997). Adjusting for
non-compliance and contamination in randomized clinical trials. Statistics in Medicine 16, 1017â€“1029.
Fisher, L. D., Dixon, D. O., Herson, J., Frankowski, R.,
Hearron, M., and Peace, K. E. (1990). Intention to treat
in clinical trials. In Statistical Issues in Drug Research
and Development, K. E. Peace (ed), 331â€“350. New York:
Marcel Dekker.
Fisher, R. A. (1935). The Design of Experiments. London:
Oliver and Boyd.
Godambe, V. P. (1960). An optimum property of regular
maximum likelihood estimation. Annals of Mathematical
Statistics 31, 1208â€“1211.
Greenland, S. (2000). An introduction to instrumental variables for epidemiologists. International Journal of Epidemiology 29, 722â€“729.
Greenland, S. and Robins, J. M. (1985). Estimation of a common eï¬€ect parameter from sparse follow-up data. Biometrics 41, 55â€“68.
Hauck, W. W. (1979). The large-sample variance of the
Mantel-Haenszel estimator of a common odds ratio. Biometrics 35, 817â€“819.
Lee, Y., Ellenberg, J., Hirtz, D., and Nelson, K. (1991). Analysis of clinical trials by treatment actually received: Is it
really an option? Statistics in Medicine 10, 1595â€“1605.
Mantel, N. and Haenszel, W. (1959). Statistical aspects of
the analysis of data from retrospective studies of disease.
Journal of the National Cancer Institute 22, 719â€“748.
Mark, S. D. and Robins, J. M. (1993). A method for the analysis of randomized trials with compliance information:

Stratiï¬ed Analysis in Randomized Trials with Noncompliance
An application to the multiple risk factor intervention
trial. Controlled Clinical Trials 14, 79â€“97.
Multiple Risk Factor Intervention Trial Research Group.
(1982). Multiple risk factor intervention trial: Risk factor
changes and mortality results. Journal of the American
Medical Association 248, 1465â€“1477.
Piantadosi, S. (1997). Clinical Trials: A Methodologic Perspective. New York: Wiley.
Radhakrishna, S. (1965). Combination of results from several
2 Ã— 2 contingency tables. Biometrics 21, 86â€“98.
Rao, C. R. (1973). Linear Statistical Inference and Its Application, 2nd edition. New York: Wiley.
Robins, J. M. and Greenland, S. (1994). Adjusting for diï¬€erential rates of PCP prophylaxis in high- versus low-dose
AZT treatment arms in an AIDS randomized trial. Journal of the American Statistical Association 89, 737â€“749.
Robins, J. M. and Tsiatis, A. A. (1991). Correcting for
non-compliance in randomized trials using rank preserving structural failure time models. Communications in
Statisticsâ€”Theory and Methods 20, 2609â€“2631.
Rothman, K. J. and Boice, J. D. (1979). Epidemiologic Analysis with a Programmable Calculator. NIH Publication.
79-1649. Washington, DC: U.S. Government Printing
Oï¬ƒce.
Sato, T. (1994). Randomized intent-to-analyses. Japanese
Journal of Applied Statistics 23, 21â€“34 (in Japanese).
Sato, T. (2000). Sample size calculations with compliance information. Statistics in Medicine 19, 2689â€“2697.
Schwartz, D. and Lellouch, J. (1967). Explanatory and pragmatic attitudes in therapeutic trials. Journal of Chronic
Diseases 20, 637â€“648.
Sheiner, L. and Rubin, D. B. (1995). Intention-to-treat analysis and the goals of clinical trials. Clinical Pharmacology
and Therapeutics 87, 6â€“15.
Received July 2003. Revised November 2004.
Accepted November 2004.

Appendix
The Optimal Weights
The asymptotic eï¬ƒciency is given by AE = N âˆ’1 E2 [dS (Ï†)/
d Ï†|Ï†=Ï†0 ]/E[S 2 (Ï†0 )], where Ï† is a causal parameter with the

823

true value of Ï†0 (Ï† is Î´ for the additive causal eï¬€ect model,
and Ï† is Ï for the multiplicative causal eï¬€ect model). We
use a ï¬xed weight wk for stratum k (k = 1, . . . , K). Under
the assumption that the incidence of an event on a participant does not aï¬€ect that on the other participants, we
have
E[S 2 (Ï†0 )] =





wk2 E

k

=


k

xâˆ—k (Ï†0 ) ykâˆ— (Ï†0 )
âˆ’
nk
mk


wk2 var

2



xâˆ—k (Ï†0 ) ykâˆ— (Ï†0 )
âˆ’
.
nk
mk

The latter expression is derived since E [xâˆ—k (Ï†0 )/nk âˆ’ yâˆ—k (Ï†0 )/
mk ] equals zero. In matrix terms, we have E[S 2 (Ï†0 )] =
1
K
w Î£w, where Î£ = diag( nN
PÌ„0,1 (1 âˆ’ PÌ„0,1 ), . . . , nKNm
PÌ„0,K Ã—
1 m1
K

(1 âˆ’ PÌ„0,K )) and w = (w1 , . . . , wK ) . Furthermore, E2 [dS (Ï†)/
d Ï†Ï†=Ï†0 ] in the numerator of AE is expressed as c (w g)2 ,
where g = (r1 , . . . , rk ) and c = 1 for the additive causal effect model and g = (s1 , . . . , sk ) and c = Ïâˆ’4
for the mul0
tiplicative causal eï¬€ect model. By applying the Cauchyâ€“
Schwartz inequality (e.g., Rao, 1973), the minimum of AE
is given by Nâˆ’1 c(GÎ£âˆ’1 G)âˆ’1 . The minimum is obtained using
a vector of weights w âˆ Î£âˆ’1 G. Therefore, we have optimal
weights, wkopt = rk nk mk /(Nk PÌ„k,0 (1 âˆ’ PÌ„k,0 )), for the additive
causal eï¬€ect model and wkopt = sk nk mk /(Nk PÌ„k,0 (1 âˆ’ PÌ„k,0 )) for
the multiplicative causal eï¬€ect model (k = 1, . . . , K). Because
the averaged baseline risk in stratum k, PÌ„k,0 , can be estimated
by {xâˆ—k (Ï†0 ) + yâˆ—k (Ï†0 )}/Nk , we have estimated weights w A
k (Î´ 0 )
or w A
k (Ï0 ).
For the additive causal eï¬€ect model, the optimal weight w opt
k
would reduce to rk nk mk /Nk , that is, w Bk , under the assumption
that PÌ„k,0 is constant for all k. Weight w opt
would reduce to
k
nk mk /(Nk PÌ„k,0 (1 âˆ’ PÌ„k,0 )), which can be estimated as w Ck (Î´ 0 ),
and weight w Bk would reduce to nk mk /Nk , that is, w D
k , under
the assumption that rk is constant for all k.
For the multiplicative causal eï¬€ect model, the optimal
weight w opt
reduces to sk nk mk /Nk , that is, w Bk , under the ask
sumption that PÌ„k,0 is constant for all k. Under the assumption
that all participants are compliant and assignment is random,
sk would converge in probability to Ï0 PÌ„k,0 , so that the weight
w opt
k would reduce to nk mk /(Nk (1 âˆ’ PÌ„k,0 )), which can be estimated as w Ck (Ï0 ), and the weight w Bk would reduce to nk mk /Nk ,
that is, w D
k.

